| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Charles Antzelevitch | Q23857055 |
| P2093 | author name string | Alexander Burashnikov | |
| P2860 | cites work | Basic Mechanisms of Cardiac Impulse Propagation and Associated Arrhythmias | Q22337019 |
| Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation | Q24243067 | ||
| Effect of dronedarone on cardiovascular events in atrial fibrillation | Q28235128 | ||
| Pulmonary vein denervation enhances long-term benefit after circumferential ablation for paroxysmal atrial fibrillation | Q28237224 | ||
| Dronedarone for atrial fibrillation--an odyssey | Q28243247 | ||
| Kv1.5 channelopathy due to KCNA5 loss-of-function mutation causes human atrial fibrillation | Q28245803 | ||
| Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter | Q28246290 | ||
| Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial [...] | Q28258503 | ||
| Increased mortality after dronedarone therapy for severe heart failure | Q28284464 | ||
| Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group | Q28372836 | ||
| Rate Versus Rhythm Control Pharmacotherapy For Atrial Fibrillation: Where are We in 2008? | Q33585592 | ||
| Synergistic electrophysiologic and antiarrhythmic effects of the combination of ranolazine and chronic amiodarone in canine atria | Q33665436 | ||
| The M cell: its contribution to the ECG and to normal and abnormal electrical function of the heart | Q33722232 | ||
| A comparison of rate control and rhythm control in patients with atrial fibrillation | Q34162727 | ||
| Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure | Q34386004 | ||
| Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. | Q34387461 | ||
| Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction | Q34415281 | ||
| Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators | Q34420012 | ||
| The G protein-gated potassium current I(K,ACh) is constitutively active in patients with chronic atrial fibrillation | Q34473254 | ||
| Rhythm or rate control in atrial fibrillation--Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial | Q34512370 | ||
| Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis | Q34558240 | ||
| Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE). | Q34577293 | ||
| Atrial-selective sodium channel block as a strategy for suppression of atrial fibrillation | Q34765700 | ||
| Rhythm control versus rate control for atrial fibrillation and heart failure | Q34787629 | ||
| A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation | Q78613787 | ||
| Model-dependent effects of the gap junction conduction-enhancing antiarrhythmic peptide rotigaptide (ZP123) on experimental atrial fibrillation in dogs | Q79562278 | ||
| Cardioversion of persistent atrial fibrillation by a combination of atrial specific and non-specific class III drugs in the goat | Q80233954 | ||
| Differences in atrial versus ventricular remodeling in dogs with ventricular tachypacing-induced congestive heart failure | Q80332145 | ||
| Role of Rac1 GTPase activation in atrial fibrillation | Q80690654 | ||
| Angiotensin II antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial: rationale and study design | Q81094969 | ||
| Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less | Q81097337 | ||
| Azd7009: a new antiarrhythmic drug with predominant effects on the atria effectively terminates and prevents reinduction of atrial fibrillation and flutter in the sterile pericarditis model | Q81174913 | ||
| Rhythm control in atrial fibrillation--one setback after another | Q81484572 | ||
| Inhibition of angiotensin II signaling and recurrence of atrial fibrillation in AFFIRM | Q81684613 | ||
| Are there atrial selective/predominant targets for "upstream" atrial fibrillation therapy? | Q81935173 | ||
| Kir3-based inward rectifier potassium current: potential role in atrial tachycardia remodeling effects on atrial repolarization and arrhythmias | Q83058608 | ||
| Rapid conversion of persistent atrial fibrillation to sinus rhythm by intravenous AZD7009 | Q83157851 | ||
| Tertiapin, a selective IKACh blocker, terminates atrial fibrillation with selective atrial effective refractory period prolongation | Q83844154 | ||
| Atrial-selective sodium channel block as a novel strategy for the management of atrial fibrillation | Q37584282 | ||
| The use of oral ranolazine to convert new or paroxysmal atrial fibrillation: a review of experience with implications for possible "pill in the pocket" approach to atrial fibrillation. | Q37599330 | ||
| Atrial remodeling and atrial fibrillation: mechanisms and implications. | Q37609710 | ||
| Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses | Q37609736 | ||
| Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial | Q38379296 | ||
| Continuous vs episodic prophylactic treatment with amiodarone for the prevention of atrial fibrillation: a randomized trial | Q38386641 | ||
| How Do Atrial-Selective Drugs Differ From Antiarrhythmic Drugs Currently Used in the Treatment of Atrial Fibrillation? | Q38790685 | ||
| Antiarrhythmic drug-induced internalization of the atrial-specific k+ channel kv1.5. | Q39851183 | ||
| The effect of ranolazine on maintaining sinus rhythm in patients with resistant atrial fibrillation | Q41178190 | ||
| Can inhibition of IKur promote atrial fibrillation? | Q41880477 | ||
| Novel transient outward and ultra-rapid delayed rectifier current antagonist, AVE0118, protects against ventricular fibrillation induced by myocardial ischemia | Q42165875 | ||
| How Do Atrial-Selective Drugs Differ From Antiarrhythmic Drugs Currently Used in the Treatment of Atrial Fibrillation? | Q42385429 | ||
| Differential phosphorylation-dependent regulation of constitutively active and muscarinic receptor-activated IK,ACh channels in patients with chronic atrial fibrillation | Q42509641 | ||
| Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators | Q42550740 | ||
| Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine | Q43196284 | ||
| Clinical trials update from the European Society of Cardiology Meeting 2009: AAA, RELY, PROTECT, ACTIVE-I, European CRT survey, German pre-SCD II registry, and MADIT-CRT. | Q43238410 | ||
| Effects of chronic gap junction conduction-enhancing antiarrhythmic peptide GAP-134 administration on experimental atrial fibrillation in dogs | Q43266235 | ||
| Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy | Q43678581 | ||
| Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study | Q43984938 | ||
| Electrophysiologic characterization of dronedarone in guinea pig ventricular cells | Q44291353 | ||
| Effects of antiarrhythmic drugs on fibrillation in the remodeled atrium: insights into the mechanism of the superior efficacy of amiodarone | Q44365422 | ||
| Reinduction of atrial fibrillation immediately after termination of the arrhythmia is mediated by late phase 3 early afterdepolarization-induced triggered activity | Q44403583 | ||
| Effects of amiodarone and dronedarone on voltage-dependent sodium current in human cardiomyocytes | Q44531866 | ||
| Atorvastatin and persistent atrial fibrillation following cardioversion: a randomized placebo-controlled multicentre study | Q44620783 | ||
| N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. | Q44754719 | ||
| Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study | Q44790546 | ||
| Characterization of a hyperpolarization-activated time-dependent potassium current in canine cardiomyocytes from pulmonary vein myocardial sleeves and left atrium | Q44799799 | ||
| Atrial fibrillation is associated with increased spontaneous calcium release from the sarcoplasmic reticulum in human atrial myocytes | Q45020424 | ||
| "Early" class III drugs for the treatment of atrial fibrillation: efficacy and atrial selectivity of AVE0118 in remodeled atria of the goat | Q45057043 | ||
| Role of IKur in controlling action potential shape and contractility in the human atrium: influence of chronic atrial fibrillation | Q45101337 | ||
| Long-term amiodarone administration remodels expression of ion channel transcripts in the mouse heart | Q45134156 | ||
| Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach | Q45170339 | ||
| Beneficial effects of intravenously administered N-3 fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a prospective randomized study | Q45733208 | ||
| Efficacy and safety of prescription omega-3-acid ethyl esters for the prevention of recurrent symptomatic atrial fibrillation: a prospective study. | Q45924828 | ||
| Valsartan for prevention of recurrent atrial fibrillation | Q46049727 | ||
| The gap junction modifier, GAP-134 [(2S,4R)-1-(2-aminoacetyl)-4-benzamido-pyrrolidine-2-carboxylic acid], improves conduction and reduces atrial fibrillation/flutter in the canine sterile pericarditis model. | Q46104609 | ||
| Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study | Q46400733 | ||
| Mechanisms of atrial fibrillation termination by rapidly unbinding Na+ channel blockers: insights from mathematical models and experimental correlates | Q46448155 | ||
| Defective cardiac ryanodine receptor regulation during atrial fibrillation | Q46455370 | ||
| Consequences of atrial electrical remodeling for the anti-arrhythmic action of class IC and class III drugs | Q46539698 | ||
| Differential behaviors of atrial versus ventricular fibroblasts: a potential role for platelet-derived growth factor in atrial-ventricular remodeling differences | Q46696420 | ||
| In vivo antiarrhythmic and cardiac electrophysiologic effects of a novel diphenylphosphine oxide IKur blocker (2-isopropyl-5-methylcyclohexyl) diphenylphosphine oxide | Q46699139 | ||
| Effects of the gap junction modifier rotigaptide (ZP123) on atrial conduction and vulnerability to atrial fibrillation | Q46781708 | ||
| Characterization of the in vivo and in vitro electrophysiological effects of the novel antiarrhythmic agent AZD7009 in atrial and ventricular tissue of the dog. | Q46902698 | ||
| In vitro and in vivo effects of the atrial selective antiarrhythmic compound AVE1231. | Q46977912 | ||
| Impact of ramipril on the incidence of atrial fibrillation: results of the Heart Outcomes Prevention Evaluation study. | Q47572885 | ||
| Functional effects of the late sodium current inhibition by AZD7009 and lidocaine in rabbit isolated atrial and ventricular tissue and Purkinje fibre | Q48632366 | ||
| Ultrarapid delayed rectifier current inactivation in human atrial myocytes: properties and consequences. | Q50741890 | ||
| Effects of WAY-123,398, a New Class III Antiarrhythmic Agent, on Cardiac Refractoriness and Ventricular Fibrillation Threshold in Anesthetized Dogs: A Comparison with UK-68798, E-4031, and dl-Sotalol | Q51679199 | ||
| ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiolog | Q51935524 | ||
| Antiarrhythmic drugs and cardiac ion channels: mechanisms of action. | Q53943964 | ||
| Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failure | Q57396308 | ||
| Antiarrhythmics After Ablation of Atrial Fibrillation (5A Study) | Q58814966 | ||
| Safe and effective conversion of persistent atrial fibrillation to sinus rhythm by intravenous AZD7009. | Q64971262 | ||
| Rate-dependent effects of the class III antiarrhythmic drug almokalant on refractoriness in the pig | Q71630211 | ||
| Antiarrhythmic and electrophysiologic effects of intravenous ibutilide and sotalol in the canine sterile pericarditis model | Q71644925 | ||
| Prolongation of the human cardiac monophasic action potential by sotalol | Q72538644 | ||
| Class III antiarrhythmic drug action in experimental atrial fibrillation. Differences in reverse use dependence and effectiveness between d-sotalol and the new antiarrhythmic drug ambasilide | Q72711505 | ||
| Ionic targets for drug therapy and atrial fibrillation-induced electrical remodeling: insights from a mathematical model | Q73112805 | ||
| Electrical heterogeneity, cardiac arrhythmias, and the sodium channel | Q73221469 | ||
| Outward K+ current densities and Kv1.5 expression are reduced in chronic human atrial fibrillation | Q73381111 | ||
| Atrial but not ventricular fibrosis in mice expressing a mutant transforming growth factor-beta(1) transgene in the heart | Q73556354 | ||
| Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators | Q73594702 | ||
| Autonomic tone variations before the onset of paroxysmal atrial fibrillation | Q74268938 | ||
| Differential atrial versus ventricular activities of class III potassium channel blockers | Q74424790 | ||
| Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort | Q77960625 | ||
| Heterogeneity of sodium current in atrial vs epicardial ventricular myocytes of adult guinea pig hearts | Q78408790 | ||
| Efficacy and safety of dofetilide in patients with atrial fibrillation and atrial flutter | Q34805855 | ||
| Assessment of the ion channel-blocking profile of the novel combined ion channel blocker AZD1305 and its proarrhythmic potential versus dofetilide in the methoxamine-sensitized rabbit in vivo | Q34987024 | ||
| Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study | Q35722724 | ||
| Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent. | Q35892164 | ||
| Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-beta1. | Q36249250 | ||
| Late-phase 3 EAD. A unique mechanism contributing to initiation of atrial fibrillation | Q36444987 | ||
| Innovative approaches to anti-arrhythmic drug therapy. | Q36670460 | ||
| Non-ion channel blockers as anti-arrhythmic drugs (reversal of structural remodeling). | Q36727629 | ||
| Amiodarone for atrial fibrillation | Q36747976 | ||
| Vernakalant (RSD1235): a novel, atrial-selective antifibrillatory agent | Q36764028 | ||
| Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations. | Q36839147 | ||
| Pathology-specific effects of the IKur/Ito/IK,ACh blocker AVE0118 on ion channels in human chronic atrial fibrillation | Q36842497 | ||
| Transmural dispersion of myofiber mechanics: implications for electrical heterogeneity in vivo | Q36948345 | ||
| Inhibition of late sodium current to reduce electrical and mechanical dysfunction of ischaemic myocardium | Q37028763 | ||
| Statins and polyunsaturated fatty acids for treatment of atrial fibrillation | Q37038371 | ||
| Atrial-selective approaches for the treatment of atrial fibrillation | Q37092378 | ||
| Atrial-selective effects of chronic amiodarone in the management of atrial fibrillation. | Q37093085 | ||
| Potassium channels in atrial fibrillation: targets for atrial and pathology-specific therapy? | Q37153066 | ||
| Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches | Q37178627 | ||
| Atrial-selective sodium channel blockers: do they exist? | Q37231700 | ||
| New drugs targeting the cardiac ultra-rapid delayed-rectifier current (I Kur): rationale, pharmacology and evidence for potential therapeutic value | Q37231704 | ||
| Oxidative stress and inflammation in atrial fibrillation: role in pathogenesis and potential as a therapeutic target | Q37268783 | ||
| Calcium handling abnormalities in atrial fibrillation as a target for innovative therapeutics. | Q37268790 | ||
| Atrial fibrillation and the expanding role of catheter ablation: do antiarrhythmic drugs have a future? | Q37275359 | ||
| Amiodarone as paradigm for developing new drugs for atrial fibrillation | Q37289179 | ||
| Potent antiarrhythmic effects of chronic amiodarone in canine pulmonary vein sleeve preparations | Q37315220 | ||
| Atrial-selective pharmacological therapy for atrial fibrillation: hype or hope? | Q37349179 | ||
| Novel approaches for pharmacological management of atrial fibrillation. | Q37481193 | ||
| Atrial-selective sodium channel block for the treatment of atrial fibrillation. | Q37494653 | ||
| Angiotensin II receptor blockers in the prevention of atrial fibrillation | Q37494662 | ||
| Early and comprehensive management of atrial fibrillation: proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled 'research perspectives in atrial fibrillation'. | Q37521378 | ||
| New pharmacological strategies for the treatment of atrial fibrillation | Q37554693 | ||
| Is there a role for statins in atrial fibrillation? | Q37573895 | ||
| Statins for prevention of atrial fibrillation after cardiac surgery: a systematic literature review. | Q37584165 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 139-148 | |
| P577 | publication date | 2010-03-01 | |
| P1433 | published in | Nature Reviews Cardiology | Q2108444 |
| P1476 | title | New developments in atrial antiarrhythmic drug therapy | |
| P478 | volume | 7 |
| Q30513464 | A computational model to predict the effects of class I anti-arrhythmic drugs on ventricular rhythms |
| Q42432616 | Acute dronedarone is inferior to amiodarone in terminating and preventing atrial fibrillation in canine atria. |
| Q42777572 | Advances in the Pharmacologic Management of Atrial Fibrillation |
| Q34383573 | Advances in the Pharmacological Treatment of Atrial Fibrillation |
| Q53820825 | Aliskiren protecting atrial structural remodeling from rapid atrial pacing in a canine model. |
| Q34682939 | Antiarrhythmic effects of simvastatin in canine pulmonary vein sleeve preparations |
| Q37627515 | Application of Traditional Chinese Medicine in Treatment of Atrial Fibrillation. |
| Q37020470 | Atrial Fibrillation as a Prognostic Indicator in Medium to Large-Sized Dogs with Myxomatous Mitral Valvular Degeneration and Congestive Heart Failure |
| Q39760319 | Atrial-selective inhibition of sodium-channel current by Wenxin Keli is effective in suppressing atrial fibrillation. |
| Q36013079 | Atrial-selective prolongation of refractory period with AVE0118 is due principally to inhibition of sodium channel activity |
| Q84032438 | Atrial-selective sodium channel block by dronedarone: sufficient to terminate atrial fibrillation? |
| Q35650683 | Atrial-selective sodium channel block strategy to suppress atrial fibrillation: ranolazine versus propafenone. |
| Q35091243 | Electrophysiologic basis for the antiarrhythmic actions of ranolazine |
| Q57283285 | German Cardiac Society Working Group on Cellular Electrophysiology state-of-the-art paper: impact of molecular mechanisms on clinical arrhythmia management |
| Q55027128 | High uric acid level predicts left atrial thrombus or spontaneous echo contrast detected by transesophageal echocardiography: Meta-analysis and systematic review. |
| Q100433653 | How a concentration-effect analysis of data from the eliglustat thorough electrocardiographic study was used to support dosing recommendations |
| Q61608647 | Is extensive atrial fibrosis in the setting of heart failure associated with a reduced atrial fibrillation burden? |
| Q38703225 | Isopimaric acid - a multi-targeting ion channel modulator reducing excitability and arrhythmicity in a spontaneously beating mouse atrial cell line |
| Q37827195 | Lone atrial fibrillation: what is known and what is to come |
| Q37844891 | Mechanisms of termination and prevention of atrial fibrillation by drug therapy |
| Q43427939 | Molecular basis for class Ib anti-arrhythmic inhibition of cardiac sodium channels |
| Q88179605 | Multiple Dose Pharmacokinetics and Safety of Sulcardine Sulfate in Healthy Chinese Male Subjects: An Open-Label Phase I Clinical Study |
| Q38069201 | New directions in antiarrhythmic drug therapy for atrial fibrillation |
| Q35489060 | Novel pharmacological targets for the rhythm control management of atrial fibrillation. |
| Q51279498 | Pharmacokinetics, safety, and tolerability of sulcardine sulfate: an open-label, single-dose, randomized study in healthy Chinese subjects. |
| Q43920140 | Potassium currents in the heart: functional roles in repolarization, arrhythmia and therapeutics |
| Q28293492 | Proton-dependent inhibition of the cardiac sodium channel Nav1.5 by ranolazine |
| Q38490444 | QT response after a test dose and during maintenance therapy with AZD1305 in patients with atrial fibrillation: a double-blind, randomized, placebo-controlled trial |
| Q38420631 | Ranolazine for the treatment of atrial fibrillation |
| Q35897567 | Rate-dependent effects of vernakalant in the isolated non-remodeled canine left atria are primarily due to block of the sodium channel: comparison with ranolazine and dl-sotalol |
| Q36570112 | Role of late sodium channel current block in the management of atrial fibrillation |
| Q38103541 | Safety and efficacy of vernakalant for acute cardioversion of atrial fibrillation: an update |
| Q34181734 | Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation. |
| Q41243959 | Synthesis of a highly water-soluble acacetin prodrug for treating experimental atrial fibrillation in beagle dogs |
| Q37993754 | Systematic review and meta-analysis of the efficacy of cardioversion by vernakalant and comparators in patients with atrial fibrillation |
| Q37005224 | TASK-1 channels may modulate action potential duration of human atrial cardiomyocytes |
Search more.